681. CRC screening with sigmoidoscopy extends life by 110 d; other cancer screening tests do not extend life.
Bretthauer M, Wieszczy P, Løberg M, et al. Estimated lifetime gained with cancer screening tests: a meta-analysis of randomized clinical trials. JAMA Intern Med. 2023;183:1196-1203. 37639247.
682. In noncardiac thoracic surgery, low-dose colchicine did not reduce AF or myocardial injury after noncardiac surgery at 14 d.
Conen D, Ke Wang M, Popova E, et al; COP-AF Investigators. Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial. Lancet. 2023;402:1627-1635. 37640035.
683. Rates of Downstream Procedures and Complications Associated With Lung Cancer Screening in Routine Clinical Practice : A Retrospective Cohort Study.
作者: Katharine A Rendle.;Chelsea A Saia.;Anil Vachani.;Andrea N Burnett-Hartman.;V Paul Doria-Rose.;Sarah Beucker.;Christine Neslund-Dudas.;Caryn Oshiro.;Roger Y Kim.;Jennifer Elston-Lafata.;Stacey A Honda.;Debra Ritzwoller.;Jocelyn V Wainwright.;Nandita Mitra.;Robert T Greenlee.
来源: Ann Intern Med. 2024年177卷1期18-28页
Lung cancer screening (LCS) using low-dose computed tomography (LDCT) reduces lung cancer mortality but can lead to downstream procedures, complications, and other potential harms. Estimates of these events outside NLST (National Lung Screening Trial) have been variable and lacked evaluation by screening result, which allows more direct comparison with trials.
684. In medical inpatients, the IMPROVE risk score had moderate predictive power for 14-d in-hospital bleeding.
Villiger R, Juillard P, Darbellay Farhoumand P, et al. Prediction of in-hospital bleeding in acutely ill medical patients: external validation of the IMPROVE bleeding risk score. Thromb Res. 2023;230:37-44. 37634309.
685. In T2DM requiring insulin initiation, icodec titrated with an app safely reduced HbA1c vs. daily basal insulin analogues at 52 wk.
Bajaj HS, Aberle J, Davies M, et al. Once-weekly insulin icodec with dosing guide app versus once-daily basal insulin analogues in insulin-naive type 2 diabetes (ONWARDS 5): a randomized trial. Ann Intern Med. 2023;176:1476-1485. 37748181.
686. Development and Validation of a Protein Risk Score for Mortality in Heart Failure : A Community Cohort Study.
作者: Kayode O Kuku.;Joseph J Shearer.;Maryam Hashemian.;Rebecca Oyetoro.;Hoyoung Park.;Brittany Dulek.;Suzette J Bielinski.;Nicholas B Larson.;Peter Ganz.;Daniel Levy.;Bruce M Psaty.;Jungnam Joo.;Véronique L Roger.
来源: Ann Intern Med. 2024年177卷1期39-49页
Heart failure (HF) is a complex clinical syndrome with high mortality. Current risk stratification approaches lack precision. High-throughput proteomics could improve risk prediction. Its use in clinical practice to guide the management of patients with HF depends on validation and evidence of clinical benefit.
687. In acute decompensated HF, adding acetazolamide to IV loop diuretics reduced congestion at 3 d across eGFR levels.
Meekers E, Dauw J, Martens P, et al. Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial. Eur Heart J. 2023;44:3672-3682. 37623428.
688. Principles for the Physician-Led Patient-Centered Medical Home and Other Approaches to Team-Based Care: A Position Paper From the American College of Physicians.
作者: Ryan Crowley.;David Pugach.;Margo Williams.;Jason Goldman.;David Hilden.;Anne Furey Schultz.;Micah Beachy.; .; .
来源: Ann Intern Med. 2024年177卷1期65-67页
Team-based care models such as the Patient-Centered Medical Home are associated with improved patient health outcomes, better team coordination and collaboration, and increased well-being among health care professionals. Despite these attributes, hindrances to wider adoption remain. In addition, some health care professionals have sought to practice independent of the physician-led health care team, potentially undermining patient access to physicians who have the skills and training to deliver whole-person, comprehensive, and longitudinal care. In this paper, the American College of Physicians reaffirms the importance of the physician-led health care team and offers policy recommendations on professionalism, payment models, training, licensure, and research to support the expansion of dynamic clinical care teams.
689. Ensuring Equitable Access to Participation in the Electoral Process: A Policy Brief From the American College of Physicians.
During the past 2 decades, voter turnout in U.S. presidential elections has ranged from 51.7% to 66.9% of the eligible population. Low voter turnout rates and inequitable electoral institutions, such as gerrymandered districts, can skew policy decisions toward the preferences of a smaller group and further exclude individuals and communities who have been historically marginalized and excluded from decision-making processes. Voting and health are directly connected through the institution of policies by ballot initiative and the election of officials who incorporate health into their platforms. They are also indirectly connected, as civic participation connects persons to their community and empowers them with agency in decision making. In this position paper, the American College of Physicians seeks to inform physicians, medical students, and other health care professionals on the links between electoral processes and health; encourage civic participation; and offer policy recommendations to support safe and equitable access to electoral participation to advance health equity for both patients and health care professionals.
690. Adoption of Internal Medicine Milestone Ratings and Changes in Bias Against Black, Latino, and Asian Internal Medicine Residents.
作者: Bradley M Gray.;Rebecca S Lipner.;Robert O Roswell.;Alicia Fernandez.;Jonathan L Vandergrift.;Marcella Alsan.
来源: Ann Intern Med. 2024年177卷1期70-82页
The 2014 adoption of the Milestone ratings system may have affected evaluation bias against minoritized groups.
691. Cumulative Incidence of Thiazide-Induced Hyponatremia : A Population-Based Cohort Study.
作者: Niklas Worm Andersson.;Jan Wohlfahrt.;Bjarke Feenstra.;Anders Hviid.;Mads Melbye.;Marie Lund.
来源: Ann Intern Med. 2024年177卷1期1-11页
According to drug labels, the frequency of thiazide-induced hyponatremia is unknown or uncommon to very rare (that is, <1 in 10 000 to <1 in 100), but the exact burden remains unclear.
692. HIV Testing and Preexposure Prophylaxis Prescriptions Among U.S. Commercially Insured Transgender Men and Women, 2014 to 2021.
作者: Ya-Lin A Huang.;Asa Radix.;Weiming Zhu.;Anne A Kimball.;Evelyn J Olansky.;Karen W Hoover.
来源: Ann Intern Med. 2024年177卷1期12-17页
Transgender persons are disproportionately affected by HIV, but preexposure prophylaxis (PrEP) use has been low in this population. Clinical encounters for gender-affirming hormone therapy (GAHT) provide opportunities for HIV prevention.
693. Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline.
作者: Ahmed Arslan Yousuf Awan.;Marina C Berenguer.;Annette Bruchfeld.;Fabrizio Fabrizi.;David S Goldberg.;Jidong Jia.;Nassim Kamar.;Rosmawati Mohamed.;Mário Guimarães Pessôa.;Stanislas Pol.;Meghan E Sise.;Ethan M Balk.;Craig E Gordon.;Gaelen Adam.;Michael Cheung.;Amy Earley.;Paul Martin.;Michel Jadoul.
来源: Ann Intern Med. 2023年176卷12期1648-1655页
The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 clinical practice guideline on prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease (CKD) is an update of the 2018 guideline from KDIGO.
694. How Would You Manage This Patient With Heart Failure With Preserved Ejection Fraction? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
作者: Gerald W Smetana.;Jennifer E Ho.;Ariela R Orkaby.;Eileen E Reynolds.
来源: Ann Intern Med. 2023年176卷12期1656-1665页
The proportion of patients with new-onset heart failure who have preserved rather than reduced left ventricular ejection fraction (HFpEF and HFrEF) has been increasing over recent decades. In fact, HFpEF now outweighs HFrEF as the predominant heart failure subtype and likely remains underdiagnosed in the community. This is due in part to an aging population and a rise in other risk factors for HFpEF, including obesity and associated cardiometabolic disease. Whereas the diagnosis of HFrEF is relatively straightforward, the diagnosis of HFpEF is often more challenging because there can be other causes for symptoms, including dyspnea and fatigue, and cardinal physical examination findings of elevated jugular venous pressure or pulmonary congestion may not be evident at rest. In 2022, the American College of Cardiology, the American Heart Association, and the Heart Failure Society of America published a comprehensive guideline on heart failure that included recommendations for the management of HFpEF. The use of diuretics for the management of congestion remained the only class 1 (strong) recommendation. New recommendations included broader use of sodium-glucose cotransporter-2 inhibitors (SGLT2i, class 2a), and angiotensin receptor-neprilysin inhibitors (class 2b). In 2023, the American College of Cardiology published an expert consensus decision pathway for the management of HFpEF that suggests treatment strategies based on sex assigned at birth, ejection fraction, clinical evidence of congestion, and candidacy for SGLT2i therapy. Here, 2 experts, a cardiologist and a geriatrician, discuss their approach to the diagnosis and management of HFpEF and how they would apply guidelines to an individual patient.
695. Management of Heart Failure in Hospitalized Patients.
Heart failure affects more than 6 million people in the United States, and hospitalizations for decompensated heart failure confer a heavy toll in morbidity, mortality, and health care costs. Clinical trials have demonstrated effective interventions; however, hospitalization and mortality rates remain high. Key components of effective hospital care include appropriate diagnostic evaluation, triage and risk stratification, early implementation of guideline-directed medical therapy, adequate diuresis, and appropriate discharge planning.
696. Development and Validation of the CANHEART Population-Based Laboratory Prediction Models for Atherosclerotic Cardiovascular Disease.
作者: Maneesh Sud.;Atul Sivaswamy.;Peter C Austin.;Todd J Anderson.;David M J Naimark.;Michael E Farkouh.;Douglas S Lee.;Idan Roifman.;George Thanassoulis.;Karen Tu.;Jacob A Udell.;Harindra C Wijeysundera.;Dennis T Ko.
来源: Ann Intern Med. 2023年176卷12期1638-1647页
Prediction of atherosclerotic cardiovascular disease (ASCVD) in primary prevention assessments exclusively with laboratory results may facilitate automated risk reporting and improve uptake of preventive therapies.
697. Endoscopic En Bloc Versus Piecemeal Resection of Large Nonpedunculated Colonic Adenomas : A Randomized Comparative Trial.
作者: Jérémie Jacques.;Marion Schaefer.;Timothée Wallenhorst.;Thomas Rösch.;Vincent Lépilliez.;Stanislas Chaussade.;Jérôme Rivory.;Romain Legros.;Jean-Baptiste Chevaux.;Sarah Leblanc.;Florian Rostain.;Maximilien Barret.;Jérémie Albouys.;Arthur Belle.;Anaïs Labrunie.;Pierre-Marie Preux.;Hugo Lepetit.;Martin Dahan.;Thierry Ponchon.;Sabrina Crépin.;Loïc Marais.;Julien Magne.;Mathieu Pioche.
来源: Ann Intern Med. 2024年177卷1期29-38页
Endoscopic resection of adenomas prevents colorectal cancer, but the optimal technique for larger lesions is controversial. Piecemeal endoscopic mucosal resection (EMR) has a low adverse event (AE) rate but a variable recurrence rate necessitating early follow-up. Endoscopic submucosal dissection (ESD) can reduce recurrence but may increase AEs.
698. Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis.
作者: Amar H Kelkar.;Edward R Scheffer Cliff.;Caron A Jacobson.;Gregory A Abel.;Stijntje W Dijk.;Eline M Krijkamp.;Robert Redd.;Joanna C Zurko.;Mehdi Hamadani.;M G Myriam Hunink.;Corey Cutler.
来源: Ann Intern Med. 2023年176卷12期1625-1637页
First-line treatment of diffuse large B-cell lymphoma (DLBCL) achieves durable remission in approximately 60% of patients. In relapsed or refractory disease, only about 20% achieve durable remission with salvage chemoimmunotherapy and consolidative autologous stem cell transplantation (ASCT). The ZUMA-7 (axicabtagene ciloleucel [axi-cel]) and TRANSFORM (lisocabtagene maraleucel [liso-cel]) trials demonstrated superior event-free survival (and, in ZUMA-7, overall survival) in primary-refractory or early-relapsed (high-risk) DLBCL with chimeric antigen receptor T-cell therapy (CAR-T) compared with salvage chemoimmunotherapy and consolidative ASCT; however, list prices for CAR-T exceed $400 000 per infusion.
699. In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069-1084. 37622681.
700. In older adults, postoperative oral haloperidol vs. antipsychotics was linked to similar risk for in-hospital adverse events.
Kim DH, Lee SB, Park CM, et al. Comparative safety analysis of oral antipsychotics for in-hospital adverse clinical events in older adults after major surgery: a nationwide cohort study. Ann Intern Med. 2023;176:1153-1162. 37665998.
|